Baseline patient characteristics stratified by the presence or absence of RASI therapy in patients with IMR
| Characteristics | Unadjusted data | IPTW | ||
| RASI (+) (n=395) | RASI (−) (n=156) | P value | P value | |
| Age, years, mean±SD | 67±11 | 71±10 | <0.001 | 0.15 |
| Gender, male/female | 301/94 | 121/35 | 0.73 | 0.47 |
| Cardiovascular risk factors | ||||
| Hypertension, n (%) | 207 (52) | 82 (53) | 0.97 | 0.65 |
| Diabetes mellitus, n (%) | 130 (33) | 49 (31) | 0.73 | 0.52 |
| Dyslipidaemia, n (%) | 157 (40) | 54 (35) | 0.26 | 0.70 |
| Current smoker, n (%) | 129 (33) | 41 (26) | 0.14 | 0.84 |
| Frailty | 9 (2) | 963) | 0.04 | 0.71 |
| BMI, kg/m2, mean±SD | 23.7±3.2 | 22.9±3.3 | 0.01 | 0.50 |
| ST segment elevation MI, n (%) | 333 (84) | 117 (75) | 0.01 | 0.46 |
| Killip classification, n (%) | 1.2±0.6 | 1.5±1.0 | <0.001 | 0.85 |
| Prior MI, n (%) | 32 (8) | 12 (8) | 0.87 | 0.57 |
| Primary PCI, n (%) | 366 (93) | 123 (79) | <0.001 | 0.24 |
| CABG, n (%) | 8 (2) | 24 (15) | <0.001 | 0.79 |
| Peak CK, IU/L | 3119±2727 | 3037±3967 | 0.78 | 0.73 |
| Serum creatinine, mg/dL | 1.07±0.83 | 1.66±1.65 | <0.001 | 0.06 |
| eGFR, mL/min/1.73 m2 | 52±20 | 40±22 | <0.001 | 0.08 |
| ACEI, n (%) ARB, n (%) | 288 (73) 109 (27) | 0 (0) 0 (0) | <0.001 <0.001 | <0.001 <0.001 |
| β-blocker, n (%) | 324 (82) | 101 (65) | <0.001 | 0.61 |
| Statins, n (%) | 282 (71) | 85 (54) | <0.001 | 0.73 |
| Initial TIMI grade flow 3, n(%) | 61 (15) | 23 (15) | 0.84 | 0.05 |
| Anterior MI, n (%) | 155 (39) | 66 (42) | 0.51 | 0.35 |
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CK, creatine kinase; eGFR, estimated glomerular filtration rate; IMR, ischaemic mitral regurgitation; IPTW, inverse probability of treatment weighted; MI, myocardial infarction; PCI, percutaneous coronary intervention; RASI, renin–angiotensin system inhibitor; TIMI, Thrombolysis In Myocardial Infarction.